Paris – Mayer Brown advised the management team of Proteor, a recognized player in the orthopedics market, as part of the group's capital restructuring following the acquisition of a stake by Eurazeo (via its Nov Santé Actions Non Cotées fund) and Crédit Mutuel Equity, alongside Bpifrance and BNP Paribas Développement, which is reinvesting in the transaction, on the occasion of the exit of Ardian, a minority shareholder since 2021.
Majority-owned by the founding family group and led by Edouard Archambaud (fourth generation of the Pierron family), Proteor aims to accelerate its development in France and internationally, while preserving its independence and remaining faithful to its mission of improving patient autonomy and quality of life.
Founded in 1913 in Saint-Apollinaire (Côte-d'Or), Proteor has become one of the leading players in the design, manufacture, and distribution of external prostheses, mainly for the lower limbs. The company is also recognized for its software suite and 3D printers that assist orthopedic technicians.
The group employs 1,100 people, operates five production sites (in France, Germany, and the United States), and has a network of nearly 100 orthopedic centers (including 85 in France), enabling it to meet the needs of its customers worldwide.
Through this transaction, the management team, alongside Eurazeo, Crédit Mutuel Equity, Bpifrance, and BNP Paribas Développement, will support the international development of the Dijon-based group, both in terms of its innovation strategy and external growth opportunities, while preserving the family shareholding structure.